Cilia and Valvular Heart Disease

纤毛和瓣膜性心脏病

基本信息

批准号：
10849234
负责人：
Russell Norris
金额：
$ 57.13万
依托单位：
MEDICAL UNIVERSITY OF SOUTH CAROLINA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-07-01 至 2026-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10849234
关键词：
Administrative Supplement Affect Animal Model Aorta Arrhythmia Automobile Driving Benign Biological Cardiac Cells Cellular Assay Cessation of life Cilia Clinical Collagen Congestive Heart Failure Connexin 43 Data Data Set Deposition Development Disease Dose Echocardiography Electrocardiogram Endocarditis Etiology Fibroblasts Fibrosis Functional disorder Future Genetic Genetic Transcription Genomics Goals Guidelines Heart Heart Atrium Heart Valve Diseases Human In Vitro Incidence Individual Left Left Ventricular Dysfunction Left atrial structure Left ventricular structure Link Mechanical Stress Mechanics Medial Mitral Valve Mitral Valve Prolapse Modeling Modification Molecular Mus Myocardial Myocardium Operative Surgical Procedures Pathogenesis Pathologic Pathway interactions Patients Population Postoperative Period Ptosis Reporting Research Risk Factors Role Sampling Secondary to Signal Transduction Specimen Stimulus Stress Stretching Structure of chordae tendineae cordis Sudden Death Surgical Management Systole Testing Therapeutic Traction United States Ventricular Ventricular Arrhythmia Work coronary fibrosis early screening epigenomics experience fibrogenesis in vitro Model in vivo insight mechanical force mouse model novel novel therapeutics papillary muscle patient population pharmacologic programs response routine screening sudden cardiac death transcriptomics

项目摘要

PROJECT SUMMARY This administrative supplement is based on the current RO1 and focuses on novel mechanisms that are contributing to fibrosis and arrythmia’s in mitral valve prolapse (MVP) patients. This supplement will focus on the consequences of a prolapsing valve on LV structure and function with a focus on regionalized LV fibrosis. Our studies will provide unique opportunities to answer questions about heart-valve diseases that heretofore have not been possible to answer. MVP is a serious clinical problem, affecting 2-3% of the human population. Its complications include congestive heart failure, endocarditis, atrial arrhythmias, and sudden death. There are no known non-surgical cures for this group of disease. The proposed work capitalizes on genetic data collected from MVP patients, which has led to uncovering novel mechanisms of valve development and disease pathogenesis. These studies hold great potential for future remedial or therapeutic insight. Our studies will additionally challenge whether current surgical guidelines for MVP should be revised.

项目概要该行政补充以现行 RO1 为基础，重点关注以下新机制：导致二尖瓣脱垂 (MVP) 患者出现纤维化和心律失常。瓣膜脱垂对左心室结构和功能的影响，重点关注局部左心室纤维化。研究将为回答迄今为止有关心脏瓣膜疾病的问题提供独特的机会无法回答。 MVP 是一个严重的临床问题，影响 2-3% 的人口，其并发症包括充血。心力衰竭、心内膜炎、房性心律失常和猝死目前尚无已知的非手术治疗方法。拟议的工作利用了从 MVP 患者收集的遗传数据，这导致了这些研究揭示了瓣膜发育和疾病发病机制的新机制。我们的研究还将挑战当前的手术是否具有未来治疗或治疗洞察力的潜力。 MVP 指南应进行修订。